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ABSTRACT 
 
Objective: To evaluate the performance of ultrasonographic estimated fetal weight (EFW) at 35+0 
- 36+6 weeks’ gestation in the prediction of small for gestational age (SGA) neonates and assess 
the additive value of first, maternal risk factors and second, fetal growth velocity between 20 and 
36 weeks’ gestation in improving such prediction. 
 
Methods: This was a prospective study of 44,043 singleton pregnancies that had undergone 
routine ultrasound examination at 19+0 - 23+6 and at 35+0 - 36+6 weeks’ gestation. Multivariable 
logistic regression analysis was used to determine whether addition of maternal risk factors and 
growth velocity, defined by a difference in EFW Z-scores or fetal abdominal circumference (AC) 
Z-scores between the third and second trimester scans divided by the time interval between them, 
improved the performance of EFW at 35+0 - 36+6 weeks in the prediction of delivery of SGA 
neonates with birthweight <10th and <3rd percentiles within two weeks and at any stage after 
assessment. 
 
Results: Screening by EFW at 35+0 - 36+6 weeks’ gestation <10th percentile predicted 63.4% (95% 
CI 62.0, 64.7) of neonates with birthweight <10th percentile and 74.2% (95% CI 72.2, 76.1) of 
neonates with birthweight <3rd percentile born at any stage after assessment, at screen positive 
rate of 10%. The respective values for SGA neonates born within two weeks of assessment were 
76.8% (95% CI 74.4, 79.0) and 81.3% (95% CI 78.2, 84.0). In the group of fetuses with EFW <10th 
percentile, 43.7% were born with birthweight ≥10th percentile. For a desired 90% detection rate of 
SGA neonates delivering at any stage after assessment the necessary screen positive rate would 
be 33.7% for SGA <10th percentile and 24.4% for SGA <3rd percentile. Multivariable logistic 
regression analysis demonstrated that in the prediction of SGA neonates with birthweight <10th 
and <3rd percentiles there was a significant contribution from EFW Z-score at 35+0 - 36+6 weeks’ 
gestation, maternal risk factors and AC growth velocity, but not EFW growth velocity. However, 
the area under the receiver operating characteristic curves for SGA neonates in screening by 
maternal risk factors and EFW Z-score was not improved by addition of AC growth velocity. 
 
Conclusion: Screening for SGA neonates by EFW at 35+0 - 36+6 weeks’ gestation and use of a 
cut-off of the 10th percentile predicts 63% of affected neonates. Prediction of 90% of SGA 
neonates necessitates classification of about 35% of the population as being screen positive use 
of the 35th percentile cut-off in EFW. The predictive performance of EFW is not improved by 
addition of estimated growth velocity between the second and third trimesters of pregnancy. 
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INTRODUCTION 
 
Small for gestational age (SGA) neonates are at increased risk of perinatal mortality and both 
short- and long-term morbidity, but these risks can be reduced if the condition is identified 
prenatally, because in such cases close monitoring and appropriate timing of delivery and prompt 
neonatal care can be undertaken.1-3 National guidelines from many developed countries define 
fetal growth restriction on the basis of ultrasonographic estimated fetal weight (EFW) <10th 
percentile and severe growth restriction as EFW <3rd percentile with recommendations on the 
time of delivery varying from 37 to 40 weeks’ gestation depending on the severity of SGA and 
fetal Doppler findings.4 However, there are several important issues that are often overlooked in 
such recommendations: first, the method of screening that leads to an ultrasound examination for 
estimation of fetal weight, second, the accuracy of such ultrasound examination, third, the 
selection of the reference ranges of EFW and birthweight for the diagnosis of SGA fetuses and 
SGA neonates, and fourth, the degree of fetal growth between assessment and delivery.  
 
In this paragraph we summarize an approach for addressing the above issues. First, the 
traditional method of identifying pregnancies with SGA fetuses is maternal abdominal palpation 
and serial measurements of symphysial-fundal height, but the predictive performance of such 
screening is poor.5,6 There is some evidence that substantially improved prediction of SGA is 
achieved by universal sonographic fetal biometry during the third trimester, especially at about 36 
weeks’ gestation;7-11 this is because 85% of SGA neonates with birth weight <10th percentile are 
born at >37 weeks’ gestation.12 Second, a systematic review of 45 studies describing a total of 70 
models for EFW by various combinations of measurements of fetal head circumference (HC), 
biparietal diameter, femur length (FL) and abdominal circumference (AC),13 reported that the most 
accurate model was provided by the formula of Hadlock et al.,14 which incorporated 
measurements of HC, AC and FL; the EFW measured within 2 days of delivery was within 10% 
of birth weight in 80% of cases.13 Third, reference ranges of EFW are representative of the whole 
population, whereas in the construction of reference ranges of birthweight, particularly for 
gestational ages at <37 weeks, there is overrepresentation of pathological pregnancies; to 
overcome this problem we proposed the use of EFW and birth weight charts with a common 
median.15 Fourth, in a previous study of 5,515 pregnancies undergoing routine ultrasound 
examination at 36 weeks’ gestation we found that EFW <10th percentile predicted 87% of SGA 
neonates born within two weeks of assessment but only 63% of those born >37 weeks’ gestation.8 
The study also reported that for a desired prediction of 90% of SGA neonates delivering >37 
weeks the necessary screen positive rates would be about 35%.8 
 
On the basis of the observed predictive performance for SGA neonates of EFW at 36 weeks’ 
gestation, compliance with national guidelines on the diagnosis and management of SGA fetuses 
would necessitate intensive monitoring and / or early iatrogenic delivery of about 35% of 
pregnancies and accepting that we would still miss about 10% of SGA neonates.8 The objectives 
of this expanded series of 44,043 singleton pregnancies are to evaluate the performance of EFW 
at 35+0 - 36+6 weeks’ gestation in the prediction of SGA neonates and assess the additive value 
of first, maternal risk factors and second, fetal growth velocity between 20 and 36 weeks’ gestation 
in improving such prediction. 
 
METHODS 
 
This was a prospective study of 44,043 singleton pregnancies that had undergone routine 
ultrasound examination at 19+0 - 23+6 and at 35+0 - 36+6 weeks’ gestation at King’s College 
Hospital, London or Medway Maritime Hospital, Gillingham, UK between October 2013 and 
September 2018. In the first visit we recorded maternal demographic characteristics and medical 
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history and in both visits we carried out an ultrasound examination for fetal anatomy and 
measurement of fetal HC, AC and FL for calculation of EFW.14 Gestational age was determined 
by the measurement of fetal crown-rump length at 11-13 weeks or the fetal head circumference 
at 19-24 weeks.16,17 The ultrasound examinations were carried out by 256 examiners who had 
obtained the Fetal Medicine Foundation certificate of competence in ultrasound examination for 
fetal abnormalities. 
 
The women gave written informed consent to participate in the study, which was approved by the 
NHS Research Ethics Committee. The inclusion criteria for this study were singleton pregnancies 
examined at both 19+0 - 23+6 and at 35+0 - 36+6 weeks’ gestation and delivering a non-malformed 
live birth or stillbirth. We excluded pregnancies with aneuploidies and major fetal abnormalities.  
 
Patient characteristics  
 
Patient characteristics recorded included maternal age, racial origin (White, Black, South Asian, 
East Asian and mixed), method of conception (natural, in vitro fertilization or use of ovulation 
induction drugs), cigarette smoking during pregnancy, medical history of chronic hypertension and 
diabetes mellitus, obstetric history including parity (parous or nulliparous if no previous 
pregnancies at > 24 weeks’ gestation), and previous pregnancy with SGA. The maternal weight 
and height were measured. 
 
Outcome measures 
 
Data on pregnancy outcome were collected from the hospital maternity records or the general 
medical practitioners of the women. The outcome measures of the study were birth of a neonate 
with birth weight <10th or <3rd percentile for gestational age at delivery.14  
 
Statistical analysis 
 
Data were expressed as median (interquartile range [IQR]) for continuous variables and n (%) for 
categorical variables. Mann-Whitney U-test and χ2-square test or Fisher’s exact test, were used 
for comparing outcome groups for continuous and categorical data, respectively. Significance was 
assumed at 5%. 
 
In the dataset of 44,043 singleton pregnancies with paired measurements of fetal biometry 
examined at 19+0 - 23+6  and 35+0 - 36+6 weeks’ gestation, the observed measurements of EFW 
and AC were expressed as Z-scores for gestational age.14,17 The a priori risk for SGA based on 
maternal factors was derived from a dataset of 124,443 singleton pregnancies at 11+0 - 13+6 
weeks’ gestation using multivariable logistic regression analysis with backward stepwise 
elimination to determine which of the factors among maternal characteristics and medical and 
obstetric history had a significant contribution in predicting SGA <10th.12 Fetal growth velocity was 
defined as the difference in EFW Z-scores or AC Z-scores between the third and second trimester 
scans divided by the time interval in days between them. Univariable and multivariable regression 
analysis was carried out to determine whether the addition of maternal factors and EFW or AC 
growth velocity to the EFW Z-score at 35+0 - 36+6 weeks’ gestation improved the performance of 
screening for SGA neonates <10th  and <3rd percentile delivering within two weeks and at any 
stage after assessment. The performance of screening was determined by receiver operating 
characteristic (ROC) curves. We estimated detection rates (95% confidence intervals [CI]) for 
fixed screen positive rate of 10% and screen positive rates (95% CI) for fixed detection rates of 
85%, 90% and 95%. 
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The statistical software package SPSS 24.0 (IBM SPSS Statistics for Windows, Version 24.0, 
Armonk, NY: IBM Corp; 2016) and Medcalc (Medcalc Software, Mariakerke, Belgium) were used 
for data analyses. 
 
RESULTS 
 
Patient characteristics 
 
The characteristics of the study population are shown in Table 1. In the group with SGA neonates, 
compared to those with birthweight ≥10th percentile, the median maternal age, weight and height, 
EFW Z-score and AC Z-score at both visits and birthweight z-score were lower, more women 
were of non-White racial origin, were smokers, had chronic hypertension, were nulliparous or 
parous with previous affected pregnancy by SGA, and less women had diabetes mellitus type 1. 
 
Prediction of SGA neonates from EFW at 35+0 - 36+6 weeks’ gestation 
 
Receiver operating characteristics curves for prediction by EFW at 35+0 - 36+6 weeks’ gestation of 
SGA neonates <10th and <3rd percentiles born within two weeks and at any time from assessment 
are shown in Figure 1. The group with EFW Z-score <-1.2106, which is equivalent to 10% of the 
population the 10th percentile, contained 63.4% (95% CI 62.0, 64.7) of neonates with birthweight 
<10th percentile and 74.2% (95% CI 72.2, 76.1) of neonates with birthweight <3rd percentile born 
at any stage after screening. The respective values for SGA neonates born within two weeks of 
screening were 76.8% (95% CI 74.4, 79.0) and 81.3% (95% CI 78.2, 84.0). In the group of fetuses 
with EFW <10th percentile, 43.7% were born with birthweight ≥10th percentile. For a desired 90% 
detection rate of SGA neonates delivering at any stage after assessment the necessary screen 
positive rate would be 33.7% for SGA <10th percentile and 24.4% for SGA <3rd percentile. 
 
Prediction of SGA neonates: additional contribution of maternal risk factors and growth velocity 
 
Multivariable logistic regression analysis demonstrated that in the prediction of SGA neonates 
with birthweight <10th and <3rd percentiles there was a significant contribution from maternal risk 
factors, EFW Z-score at 35+0 - 36+6 weeks’ gestation and AC growth velocity, but not EFW growth 
velocity (Table 2). 
 
The AUROC for SGA neonates <10th percentile born within two weeks from assessment in 
screening by maternal risk factors and EFW Z-score (0.936, 95% CI 0.929, 0.943) was marginally 
higher than that of screening by EFW Z-score alone (0.933, 95% CI 0.926, 0.941; p=0.040); the 
AUROC in screening by maternal risk factors and EFW Z-score was not improved by addition of 
AC growth velocity (p=0.232). In prediction of SGA neonates <3rd percentile, addition of maternal 
risk factors did not improve the performance of screening that was achieved by EFW Z-score 
alone (p=148) and addition of AC growth velocity did not improve the performance of screening 
that was achieved by a combination of maternal risk factors and EFW Z-score (p=0.058) (Table 
3).  
 
The AUROC for SGA neonates <10th percentile born at any time from assessment in screening 
by a combination of maternal risk factors and EFW Z-score at 35+0 - 36+6 weeks (0.895, 95% CI 
0.890, 0.899) was significantly higher than that of screening by EFW Z-score alone (0.883, 95% 
CI 0.879, 0.888 p<0.0001); this was also the case for SGA neonates <3rd percentile (0.924, 95% 
CI 0.919, 0.930 vs. 0.918, 95% CI 0.912, 0.923; p<0.001) (Table 3). Addition of AC growth velocity 
did not improve the performance of screening that was achieved by a combination of maternal 
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risk factors and EFW Z-score, for prediction of either SGA neonates <10th percentile (p=0.103) or 
<3rd percentile (p=0.061) (Table 3). 
 
The detection rate, at 10% screen positive rate, of SGA neonates <10th percentile born within two 
weeks from assessment, in screening by EFW alone (76.8%) was marginally improved by the 
addition of maternal risk factors (78.6%), but addition of AC growth velocity (78.6%) did not 
improve the detection rate that was achieved by a combination of maternal risk factors and EFW 
Z-score. In the case of SGA neonates <3rd percentile the detection rate in screening by EFW 
alone (81.7%) was not improved by the addition of maternal risk factors (81.7%) or the addition 
of maternal risk factors and AC growth velocity (82.1%) (Table 3). The detection rate, at 10% 
screen positive rate, of SGA neonates <10th percentile born at any stage after assessment, in 
screening by EFW alone (63.4%) was significantly improved by the addition of maternal risk 
factors (67.1%), but addition AC growth velocity (67.1%) did not improve the detection rate 
achieved by a combination of maternal risk factors and EFW (Table 3). In the case of SGA 
neonates <3rd percentile the detection rate, at 10% screen positive rate, in screening by EFW 
alone (74.2%) was marginally improved by the addition of maternal risk factors (75.9%), and 
addition AC growth velocity (76.4%) did not improve the detection rate achieved by a combination 
of maternal risk factors and EFW (Table 3). 
 
The screen positive rates necessary to achieve prediction of 85%, 90% and 95% of SGA neonates 
delivering within two weeks and at any stage from assessment are shown in Table 4. If the desired 
detection rate of SGA neonates <10th percentile born within two weeks from assessment was 
90%, the necessary screen positive rate in screening by maternal risk factors and EFW was not 
significantly different from that of screening by EFW alone (20.7% vs 21.3%); this was also the 
case for SGA neonates <3rd percentile (16.0% vs. 17.2%). However, for SGA neonates <10th 
percentile born at any stage from assessment the necessary screen positive rate for 90% 
detection rate in screening by maternal risk factors and EFW was lower than that of screening by 
EFW alone (31.0% vs 33.7%; p<0.001); this was also the case for SGA neonates <3rd percentile 
(20.8% vs. 24.4%; p<0.001). 
 
DISCUSSION 
 
Main findings of the study 
 
The findings of this study demonstrate the performance of screening for SGA neonates by routine 
ultrasound examination at 35+0 - 36+6 weeks’ gestation. Screening by EFW, at 10% screen positive 
rate, at EFW cut-off of the 10th percentile predicted 63% of neonates with birthweight <10th 
percentile and 74% of those with birthweight <3rd percentile born at any stage after screening; 
44% of fetuses thought to be SGA were born with birthweight ≥10th percentile. The performance 
of EFW <10th percentile was better for babies born within two weeks of assessment with prediction 
of 77% of neonates with birthweight <10th percentile and 81% of those with birthweight <3rd 
percentile. To accomplish a detection rate of 90% for SGA neonates at the 35+0 - 36+6 weeks’ scan 
we would need to classify about 35% of the population as being screen positive need to utilize 
the EFW cut-off at the 35th percentile. 
Prediction of 90% of SGA neonates necessitates  
 
The predictive performance for SGA neonates of EFW at 35+0 - 36+6 weeks’ gestation was 
improved by addition of maternal demographic characteristics and medical history; addition of 
maternal risk factors improved the prediction of SGA neonates with birthweight <10th percentile 
born at any stage after screening from 63% to 67%. We have previously reported that the risk of 
delivering SGA neonates increases with maternal age, decreases with maternal weight and 
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height, it is higher in women of Black, South Asian, East Asian and mixed racial origins than in 
White women, in cigarette smokers, in those with chronic hypertension, diabetes mellitus type II 
and in parous women with prior history of SGA. The risk is lower in parous women without prior 
history of SGA and in those with diabetes mellitus type I.12  
 
The predictive performance for SGA neonates of EFW at 35+0 - 36+6 weeks’ gestation was not 
improved by addition of fetal growth velocity between 19+0 - 23+6  and 35+0 - 36+6 weeks’ gestation. 
 
Comparison with findings from previous studies 
 
Our findings that EFW <10th percentile predicts 63% and 74% of neonates with birthweight <10th 
and <3rd percentile, respectively, are consistent with the results of previous late third-trimester 
studies. Fadigas et al, examined 5,515 pregnancies at 35-37 weeks and reported that EFW <10th 
percentile predicted 63% and 73% of neonates with birthweight <10th and <3rd percentile, 
respectively.8 Triunfo et al, examined 946 pregnancies at 36-38 weeks and reported that EFW 
<10th percentile predicted 59% and 83% of neonates with birthweight <10th and <3rd percentile, 
respectively.18 Souka et al, examined 2,288 pregnancies at 34-37 weeks and reported that EFW 
<10th percentile predicted 75% of neonates with birthweight <5th percentile.7 
 
Our findings that the prediction of SGA neonates provided by EFW is improved by the addition of 
maternal risk factors (63% to 67% for SGA <10th percentile) are consistent with the results of 
Fadigas et al, who reported that addition of maternal factors improved the prediction of SGA 
neonates from 63% to 66%.8 
 
We found that growth velocity between the second and third trimesters did not improve the 
prediction of SGA neonates provided by EFW at 35+0 - 36+6 weeks’ gestation. Studies examining 
fetal growth velocity and conditional fetal growth percentiles, which are calculated taking into 
account an EFW earlier in pregnancy, compared with conventional weight-for-gestational-age 
charts, have reported contradictory results in the prediction of adverse perinatal outcomes.11,19-22 
However, the objective of our study was to predict SGA neonates rather than adverse perinatal 
outcome. Our results are consistent with those of two previous studies that examined 3,440 and 
2,696 pregnancies, respectively,23,24 and reported that growth velocity, conditional growth 
percentiles or serial fetal biometry did not improve the prediction of SGA neonates provided by 
the last EFW alone.  
 
Implications for clinical practice 
 
In the proposed new pyramid of pregnancy care,25 an integrated clinic at 11-13 weeks’ gestation, 
in which biophysical and biochemical markers are combined with maternal characteristics and 
medical history, aims to identify pregnancies at high-risk of preterm PE and / or SGA and through 
pharmacological intervention to reduce the prevalence of these complications.26-29 The objective 
of subsequent visits, at around 20 and 32 or 36 weeks’ gestation, are to identify the high-risk 
group and through close monitoring of such pregnancies to minimize adverse perinatal events by 
determining the appropriate time and place for iatrogenic delivery. We have previously proposed 
that assessment at 20 weeks’ gestation would stratify the population into a high-risk group, which 
would comprise of <0.5% of all pregnancies and contain all cases of SGA delivering <32 weeks, 
a moderate-risk group comprising of about 15% of pregnancies and containing about 90% of 
cases of SGA that deliver at 32-36 weeks and a low-risk group that would contain all cases  of 
SGA that deliver at term.30 The high-risk group would require reassessment at 26-30 weeks and 
again at 32 and 36 weeks if not delivered, the moderate-risk group would be reassessed at 32 
and 36 weeks and the low-risk group would be reassessed at 36 weeks. 
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This study provides the necessary data for development of policies to achieve prenatal prediction 
of a desired percentage of SGA neonates near term. We have shown that the prediction of SGA 
neonates achieved by EFW can be improved by maternal factors but not by growth velocity. In a 
previous study we have reported that the prediction by EFW and maternal factors can be improved 
marginally by the addition of biomarkers of impaired placentation, including serum placental 
growth factor and uterine artery and fetal middle cerebral artery pulsatility index.12 
 
Strengths and limitations of the study 
 
The strengths of this screening study for SGA neonates are first, examination of a large population 
of pregnant women attending for routine assessment of fetal growth and wellbeing at both 19+0 - 
23+6  and 35+0 - 36+6 weeks’ gestation, second, trained sonographers that carried out fetal biometry 
according to a standardized protocol and use of a widely used model for calculation of EFW 14 
which has been shown to be the most accurate one among 70 previously reported models,13 third, 
use of the Fetal Medicine Foundation fetal and neonatal references ranges which have a common 
median.15  
 
A potential limitation of the study is the long interval between the two ultrasound examinations 
that defined growth velocity and the proximity of the second scan to delivery which would 
inevitably minimize the contribution of growth velocity to that of EFW at 35-37 weeks. This was 
the consequence of the design of our study which relied on data obtained from two routine 
ultrasound examinations in pregnancy. The extent to which a shorter interval between the two 
scans improves the contribution of growth velocity to the prediction of SGA remains to be 
determined. The second potential limitation of the study is the use of growth velocity rather than 
more complex methods of evaluating longitudinal growth; however, there is no evidence of 
superiority of the latter over the former.24,31-33  
 
Conclusions 
 
The performance of sonographic EFW for prediction of SGA neonates is highest if the interval 
between assessment and birth is short. Since 85% of SGA neonates are born at ≥37 weeks’ 
gestation a routine third trimester scan is best performed at 36 than at 32 weeks’ gestation. The 
performance of screening by EFW at 35+0 - 36+6 weeks is improved by maternal demographic 
characteristics and medical history but not by growth velocity between the second and third 
trimesters. Our results suggest, that to accomplish a detection rate of 90% for SGA neonates at 
the 35+0 - 36+6 weeks’ scan we would need to classify about 35% of the population as being screen 
positive will need to utilize the EFW cut-off at the 35th percentile. Future studies will investigate 
whether growth velocity improves the performance of the 35+0 - 36+6 weeks’ scan in the prediction of 
adverse perinatal outcome. 
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FIGURE LEGENDS 
 
Figure 1. Receiver operating characteristics curves of maternal factors (black line), estimated 
fetal weight at 35+0 - 36+6 weeks’ gestation (blue), abdominal circumference growth velocity 
(green), and combination of the three (red), in the prediction of small for gestational age neonates 
with birth weight below the 10th percentile delivering within two weeks (left) and at any time (right) 
from assessment. 
 
Figure 2. Receiver operating characteristics curves of maternal factors (black line), estimated 
fetal weight at 35+0 - 36+6 weeks’ gestation (blue), abdominal circumference growth velocity 
(green), and combination of the three (red), in the prediction of small for gestational age neonates 
with birth weight below the 3rd percentile delivering within two weeks (left) and at any time (right) 
from assessment. 
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Table 1- Maternal and pregnancy characteristics in pregnancies delivering small for gestational 
age neonates <10th percentile and those without 
 
 
GA = gestational age; EFW = estimated fetal weight; IQR = interquartile range; SGA = small for 
gestational age; PE = preeclampsia. 
  
  
Characteristic 
Non-SGA 
(n=38,994) 
SGA<10th percentile 
(n=5,049) 
P-value 
Maternal age in years, median (IQR) 31.7 (27.5, 35.4) 30.9 (26.2, 35.0) <0.001 
Maternal weight in Kg, median (IQR) 80.0 (71.5, 91.0) 73.4 (65.5, 83.4) <0.001 
Maternal height in cm, median (IQR) 165 (161, 170) 163 (158, 167) <0.001 
Racial origin    
   White, n (%) 29,825 (76.5) 3,224 (63.9) <0.001 
   Black, n (%) 5,684 (14.6) 1,055 (20.9) <0.001 
   South Asian, n (%) 1,594 (4.1) 467 (9.2) <0.001 
   East Asian, n (%) 761 (2.0) 121 (2.4) 0.034 
   Mixed, n (%) 1,130 (2.9) 182 (3.6) 0.005 
Cigarette smoker, n (%) 2,832 (7.3) 726 (14.4) <0.001 
Conception    
   Natural, n (%) 37,645 (96.5) 4,851 (96.1)  
   Ovulation drugs, n (%) 219 (0.6) 34 (0.7) 0.323 
   In vitro fertilization, n (%) 1,130 (2.9) 164 (3.2) 0.165 
Medical conditions    
   Chronic hypertension, n (%) 459 (1.2) 88 (1.7) 0.001 
   Diabetes mellitus type 1, n (%) 156 (0.4) 5 (0.1) 0.001 
   Diabetes mellitus type 2, n (%) 178 (0.5) 18 (0.4) 0.315 
Past obstetric history    
   Nulliparous, n (%) 17,114 (43.9) 2,811 (55.7) <0.001 
   Parous with prior SGA, n (%) 2,989 (7.7) 920 (18.2) <0.001 
   Parous without prior SGA, n (%) 18,891 (48.4) 1,318 (26.1) <0.001 
GA at screening at 19+0 – 23+6 weeks, median (IQR)  21.7 (21.1, 22.1) 21.7 (21.1, 22.1) 0.003 
EFW Z-score at 19+0 – 23+6 weeks, median (IQR) 0.06 (-0.58, 0.69) -0.56 (-1.17, 0.07) <0.001 
AC Z-score at 19+0 – 23+6 weeks, median (IQR) -0.01 (-0.29, 0.28) -0.24 (-0.52, 0.04) <0.001 
GA at screening at 35+0-36+6 weeks, median (IQR)  36.1 (35.9, 36.4) 36.1 (35.9, 36.4) 0.003 
EFW Z-score at 35+0-36+6 weeks, median (IQR) 0.20 (-0.39, 0.81) -1.20 (-1.88, -0.65) <0.001 
AC Z-score at 35+0-36+6 weeks , median (IQR) 0.00 (-0.47, 0.49) -1.01 (-1.49, -0.57) <0.001 
GA at delivery in weeks, median (IQR) 40.0 (39.0, 40.9) 39.4 (38.2, 40.3) <0.001 
Birthweight Z-score, median (IQR) 0.13 (-0.45, 0.75) -1.72 (-2.14, -1.48) <0.001 
Birthweight in grams, median (IQR) 3490 (3220, 3790) 2715 (2510, 2860) <0.001 
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Table 2. Multivariable logistic regression analysis in prediction of small for gestational age neonates 
<10th and <3rd percentiles from maternal and pregnancy characteristics, estimated fetal weight Z-score 
at 35+0 - 36+6 weeks’ gestation, estimated fetal weight growth velocity and abdominal circumference 
growth velocity. 
 
Characteristic 
Univariable Multivariable 
OR (95% CI) P value OR (95% CI) P value 
Birthweight <10th percentile     
Maternal factors 17.98 (16.01-20.21) <0.001 6.82 (5.94-7.82) <0.001 
Estimated fetal weight Z-score 0.15 (0.14-0.16) <0.001 0.18 (0.16-0.19) <0.001 
Estimated fetal weight growth velocity 8.12e-41 (3.16e-42-2.08e-39) <0.001 - - 
Abdominal circumference growth velocity 8.46e-80 (4.36e-82-1.64e-77) <0.001 2.10e-04 (7.50e-08-0.584) 0.036 
     
Birthweight <3rd percentile     
Maternal factors 21.59 (18.07-25.08) <0.001 5.42 (4.41-6.67) <0.001 
Estimated fetal weight z-score 0.15 (0.14-0.16) <0.001 0.18 (0.17-0.20) <0.001 
Estimated fetal weight growth velocity 9.18e-50 (7.75e-52-1.09e-47) <0.001 - - 
Abdominal circumference growth velocity 2.17e-91 (1.06e-94-4.45e-88) <0.001 4.47e-09 (3.71e-14-0.001) 0.001 
 
OR = odds ratio; CI = confidence interval; SGA = small for gestational age 
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Table 3. Performance of prediction of small for gestational age neonates with birth weight <10th, 
and <3rd percentile delivering within two weeks and at any stage after screening at 35+0 – 36+6 
weeks’ gestation. 
 
 
AUROC = area under the receiver operating characteristic curves; CI = confidence interval; EFW 
= estimated fetal weight; AC = abdominal circumference; SGA = small for gestational age; DR = 
detection rate; SPR = screen positive rate  
 
  
Screening test 
SGA <10th percentile SGA < 3rd percentile 
AUROC curve 
(95% CI) 
DR at 10% SPR 
% (95% CI) 
AUROC curve 
(95% CI) 
DR at 10% SPR 
% (95% CI) 
SGA within 2 weeks     
EFW Z-score at 35+0 - 36+6 weeks 0.933 (0.926, 0.941) 76.8 (74.4, 79.0) 0.945 (0.937, 0.952) 81.3 (78.2, 84.0) 
Maternal factors  0.693 (0.675, 0.710) 30.3 (27.7, 32.5) 0.695 (0.673, 0.717) 30.3 (27.1, 33.8) 
EFW growth velocity 0.828 (0.815, 0.842) 55.4 (53.6, 57.1) 0.856 (0.840, 0.871) 57.9 (54.4, 60.7) 
AC growth velocity 0.884 (0.873, 0.895) 64.3 (62.0, 66.7) 0.900 (0.888, 0.913) 70.9 (67.1, 73.4) 
EFW Z-score + Maternal factors 0.936 (0.929, 0.943) 78.6 (76.1, 80.7) 0.946 (0.939, 0.954) 81.7 (78.7, 84.5) 
EFW Z-score + AC growth velocity + 
Maternal factors 
0.936 (0.929, 0.944) 78.6 (76.1, 80.7) 0.947 (0.940, 0.954) 82.1 (79.1, 84.9) 
SGA at any stage     
EFW Z-score at 35+0 - 36+6 weeks 0.883 (0.879, 0.888) 63.4 (62.0, 64.7) 0.918 (0.912, 0.923) 74.2 (72.2, 76.1) 
Maternal factors  0.713 (0.706, 0.721) 31.6 (30.0, 32.6) 0.726 (0.715, 0.738) 33.9 (31.7, 35.9) 
EFW growth velocity 0.737 (0.730, 0.744) 36.7 (34.2, 38.5) 0.793 (0.782, 0.803) 47.5 (45.2, 49.7) 
AC growth velocity 0.808 (0.802, 0.814) 47.0 (45.1, 49.4) 0.855 (0.847, 0.864) 58.4 (56.1, 60.7) 
EFW Z-score + Maternal factors 0.895 (0.890, 0.899) 67.1 (65.9, 68.4) 0.924 (0.919, 0.930) 75.9 (74.0, 77.8) 
EFW Z-score + AC growth velocity + 
Maternal factors 
0.895 (0.890, 0.899) 67.1 (65.9, 68.4) 0.925 (0.919, 0.930) 76.4 (74.5, 78.3) 
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Table 4. Screen positive rate necessary to achieve prediction of 85%, 90% and 95% of small for 
gestational age neonates delivering within two weeks and at any stage after assessment at 35+0 – 36+6 
weeks’ gestation. 
 
SPR = screen positive rate; CI = confidence interval; SGA = small for gestational age; EFW = estimated 
fetal weight; AC = abdominal circumference; DR = detection rate. 
 
 
 
 
Screening test 
SPR for 85% DR 
% (95% CI) 
SPR for 90% DR% 
(95% CI) 
SPR for 95% 
DR% (95% CI) 
SGA within 2 weeks  
SGA <10th percentile  
EFW Z-score at 35+0 - 36+6 weeks 16.0 (14.9, 17.2) 21.3 (20.0, 22.6) 31.2 (29.7, 32.6) 
EFW Z-score + Maternal factors 14.6 (13.5, 15.7) 20.7 (19.4, 22.0) 30.8 (29.3, 32.2) 
EFW Z-score + Maternal factors + 
AC growth velocity 
14.4 (13.3, 15.5) 20.6 (19.3, 21.9) 30.5 (29.0, 31.9) 
SGA <3rd percentile    
EFW Z-score at 35+0 - 36+6 weeks 12.5 (11.5, 13.5) 17.2 (16.1, 18.4) 24.0 (22.8, 25.3) 
EFW Z-score + Maternal factors 11.6 (10.7, 12.6) 16.0 (14.9, 17.1) 22.3 (21.1, 23.5) 
EFW Z-score + Maternal factors + 
AC growth velocity 
11.4 (10.5, 12.4) 15.9 (14.8, 17.0) 21.2 (20.0, 22.5) 
SGA at any stage  
SGA <10th percentile  
EFW Z-score at 35+0 - 36+6 weeks 26.3 (26.0, 27.1) 33.7 (33.2, 34.2) 46.3 (45.8, 46.8) 
EFW Z-score + Maternal factors 23.3 (22.8, 23.7) 31.0 (30.6, 31.5) 42.0 (41.5, 42.4) 
EFW Z-score + Maternal factors + 
AC growth velocity 
23.0 (22.6, 23.4) 31.1 (30.7, 31.6) 41.8 (41.3, 42.5) 
SGA <3rd percentile    
EFW Z-score at 35+0 - 36+6 weeks 17.7 (17.3, 18.0) 24.4 (24.1, 24.9) 35.4 (34.9, 35.8) 
EFW Z-score + Maternal factors 15.9 (15.6, 16.3) 20.8 (20.5, 21.0) 31.8 (31.4, 32.2) 
EFW Z-score + Maternal factors + 
AC growth velocity 
15.8 (15.5, 16.2) 21.6 (21.2, 22.0) 32.5 (32.0, 32.9) 
